PharmaVentures

PharmaVentures
  • ٥٫٠ (١)
  • الأعمال
  • يتم التحديث شهريًا

PharmaVentures is a premier transaction advisory firm; a world leader in partnering, M&A deals and strategic alliances.

  1. ١٥‏/١٢‏/٢٠٢٥

    How Strategy and Communication Expedite Deal Outcomes

    Adrian Dawkes talks to PharmaVentures' Founder and CEO, Dr Fintan Walton, about the importance of strategy and preparation in today's deal making space. In the competitive, fast-paced environment of deal making within the life sciences industry, if you fail to prepare, then you must prepare to fail. Tune in to help assemble your strategy for success.

    ٢٥ د

  2. ٠٥‏/١١‏/٢٠٢٥

    Pharmaceutical Manufacturing: Adaptation Is the Key to Survival

    Join Adrian Dawkes, Managing Director at PharmaVentures, for this podcast episode exploring how the pharmaceutical manufacturing sector is evolving in response to shifting global pressures. Our experts, Ross Jenkins and Dr Gurdas Singh, unpack the critical changes shaping the industry.

    ٣٩ د

  3. ٢٢‏/٠٩‏/٢٠٢٥

    Drug Pricing: Europe vs. US, PBMs, and Direct-to-Patient

    Adrian Dawkes talks to recently appointed PharmaVentures' Vice President, Samara Ferguson, about a hot, often controversial topic: the price of medicines.

    ٣٢ د

  4. ٣٠‏/٠٤‏/٢٠٢٥

    Navigating Risk in Times of Increased Uncertainty

    Adrian Dawkes talks to PharmaVentures Founder and CEO Fintan Walton about how companies can navigate risk and even deploy new strategies in times of increased uncertainty. With the threat of tariffs, a global trade war and unease in the financial markets this podcast explores the ways companies can gain advantage over their competitors and survive when geo-politics and high levels of volatility in the financial markets throws chaos and uncertainty into strategies adopted and deployed in more normal times.

    ٣١ د

  5. ٣٠‏/١٢‏/٢٠٢٤

    Global Drug Shortages; What are the causes and how do we fix them?

    Fintan Walton, founder and CEO of PharmaVentures chairs a round table discussion on this pressing issue.   Featuring; Jim Gale. Managing Partner, Signet Healthcare Partners. A New York based Private equity firm with a wide portfolio including API medchem, Pharma Services and CDMO businesses. Andreas Raabe: Founder & CEO of Adragos Pharma, a CDMO manufacturing in the EU and Japan. Frank Dollard: 45 years of experience in pharmaceutical manufacturing, including GSK, BMS and Teva. Soren Demin: Managing Director & Head of M&A at PharmaVentures and formerly senior commercial positions in multiple pharma business and a qualified medical practitioner.   In a wide-ranging discussion, hear the panelist's views on; What is meant by "drug shortages" and where has the system failed? Where are the pinch points; manufacture, supply chains, pharma-centric influences, geopolitical events? The impact on manufacturers of the US Biosecure Act. The knock-on effects of pricing pressure on raw material sourcing. Increasing capacity & the role of M&A Can technology and innovation solve the problems? Where are the opportunities emerging from that will provide the solutions?

    ٥٣ د

  6. ١٦‏/١٢‏/٢٠٢٤

    Adrian Dawkes talks to PharmaVentures Founder and CEO Fintan Walton about his experience from over 30 years of dealmaking.

    Adrian Dawkes talks to PharmaVentures Founder and CEO Fintan Walton about his experience from over 30 years of dealmaking. In particular, why innovator biotechs and their investors are weaker when they underestimate the significance of both understanding and communicating their commercial strategy for their lead assets in negotiations. Hear about: • Failing to understand the inherent risks at the commercial stage is a failure of investment logic. • Why you shouldn't expect a potential partner to have any answers to the commercial path and success of your asset • Why you should know where your assets fit in the market landscape and what differentiates it commercially. • How to apply commercial strategic thinking to very early-stage assets.  • How planning to avoid commercial risk reduces investment risk.

    ٢٠ د

  7. ٢١‏/١٠‏/٢٠٢٤

    How is AI changing drug discovery today and where will it go from here?

    Listen as Adrian Dawkes talks to Kurt Herpel, CEO and Klaus Kratochwill, CSO of Delta 4, an Austrian /Swiss based AI tech company. Hear how their AI journey began more than 20 years ago and how the company developed into a key player in AI drug discovery. Hear how their clients are already benefiting from AI. You will hear their insights into; • Where AI is benefiting drug discovery processes today? • How will it be used in the future, will we get better drugs faster? • Can it replace the need for human involvement? • Will AI impact on the discovery and use of new biomarkers? To find out what the diagnostics deal making landscape looks like for you, you can request an initial complimentary consultation with the experts in this podcast via email: enquiries@pharmaventures.com About the Presenter: Adrian Dawkes is a Managing Director at PharmaVentures and has been with the company since 2007. Adrian has led multiple consultancy, licensing and M&A mandates. During his professional career, .Adrian has significant multi-discipline expertise spanning research and development through to sales, marketing and business development. Adrian has over 30 years' experience in the pharmaceutical, biotechnology and consultancy services sectors. Adrian holds a BSc in Biochemistry and a PhD in Immunochemistry

    ٤٢ د

  8. ٢٤‏/٠٩‏/٢٠٢٤

    Pharma/Biotech M&A: Insights and Trends with Soren Demin

    Listen as Soren Demin draws on his 20 years of M&A experience to provide insight into the current Pharma/Biotech M&A landscape. Key topics include; Is the M&A landscape recovering and will we see record activity again? How has the big pharma model changed and what is the impact on deal making? What is the direction of travel for deal volumes and values? How do biotechs position themselves to get the best deals? Who holds the upper hand, buyers or sellers? What does M&A look like for hot and emerging sectors such as AI drug discovery and Advanced Therapies? To find out what the diagnostics deal making landscape looks like for you, you can request an initial complimentary consultation with the experts in this podcast via email: enquiries@pharmaventures.com   About the Interviewees: Soren Demin is a Managing Director at PharmaVentures, where he excels in creating and unlocking value for clients through M&A, business development, and licensing. He joined PharmaVentures in 2024, bringing over 15 years of global experience in the biopharma industry. Soren’s successful industry and investment banking career, combined with his advisory and medical background, is crucial for understanding clients’ needs and providing optimized solutions. Before this role, Soren served as Chief Business Officer at the private equity-backed Essential Pharma. He also held the position of Commercial Director at the UK government’s biological manufacturing unit, Porton BioPharma, where he established new strategic collaborations and directed product development and manufacturing. Previously, Soren was part of Mitsubishi Tanabe and the Piramal Group Soren began his M&A career at Goldman Sachs, focusing on cross-border deal origination across the US, MENA, Europe, and Asia, before which he studied for a Bachelor of Medicine at the University of Sheffield and a PhD in Biotechnology from the University of Cambridge.   About the Presenter: Adrian Dawkes is a Managing Director at PharmaVentures and has been with the company since 2007. Adrian has led multiple consultancy, licensing and M&A mandates. During his professional career, Adrian has significant multi-discipline expertise spanning research and development through to sales, marketing and business development. Adrian has over 30 years' experience in the pharmaceutical, biotechnology and consultancy services sectors. Adrian holds a BSc in Biochemistry and a PhD in Immunochemistry.

    ٢٩ د
مشاهدة الكل (٢٢)

حول

PharmaVentures is a premier transaction advisory firm; a world leader in partnering, M&A deals and strategic alliances.

المعلومات

  • صناع العمل
    PharmaVentures
  • سنوات النشاط
    ٢٠٢٣ - ٢٠٢٥
  • الحلقات
    ٢٢
  • التقييم
    ملائم
  • حقوق النشر
    © All rights reserved
  • موقع البرنامج على الويب
    PharmaVentures